6 events in Passaic County with a date

15 drugs to see reduced Medicare prices in 2027

By: James Powel
USA today

..... The centers for Medicare and Medicare Services announced November 25 [2025] that prescription drugs, including popular weigh-loss medications OPzempic and Wegovy, asthma treatments and chemotherapy drugs.
..... Changes go into effect in 2027.
..... In 2024, the negotiated drug accounted for about $42.5 billion in prescription spending for the roughly 5.3 million people with Medicare Part D coverage, according to a news release. A fact sheet issued with the announcement says Medicare will save about $12 billion in costs once the new pricing kicks in and that Part D recipients will save about $685 million on out-of-pocket costs.
..... The reduced prices were negotiated through the Medicare Drug Price Negotiation Program created by the Inflation Reduction Act signed into law under the Biden administration in 2022.
..... The legislation ordered the secretary of Helaht and Human Services to negotiate reduced prices for 10 drugs to take effect in 2026, 15 drugs to take effect in 2027, and another 15 drugs with prices taking effect in 2028. Prising for 20 more drugs will take effect in 2029, according to congressional analysis.
..... The projected 2027 savings of 36% is better than the 22% savings of net spending, according to an estimate from Goldman Sachs, the Medicare achieved with the first round of price negotiations in 2024 for 10 different drugs.
..... Medicare negotiated under the Biden administration, such as the Pfizer and Bristol Myers Squibb blood thinner eliquis and Amgen's arthritis drug Enbrel, will still cost, on average, more than double - and some cases five times - what drug-makers had agreed to in other high-income countries.
..... AstraZeneca's leukemia drug Calquence, Boehringer's lung treatment Ofev and Pfizer's breast cancer drug Ibrance took the biggest hits form this round of Medicare negotiations. Each was slashed by over $4,000 form estimate net prices.
..... "They are getting ore efficient with their methodology," but this latest batch of newer products likely had "more wiggle room" on price, William Padula, professor of pharmaceutical and health economic at the University of Southern California , told Reuters.

List of negotiated drugs

..... Below are the costs of a 30-day supply of the 15 drugs that were included in the negotiations:

* Ozempic, Rybelus and Wegovy: negotiated price $274, list price $959.

* Trelegy ellipta: negotiated price $175, list price $654.

* Xtandi: negotiated price $7,004, list price $13,480.

* Pomalyst: negotiated price $8,650, list price $21,744.

* Ofev: negotiated price $6,350, list price $12,622.

* Ibrance: negotiated price $7,871, list price 415,741.

* Linzess: negotiated price $136, list price $539.

* Calquence: negotiated price $8,600, list price 414,228.

* Austedo and Austedo XR: negotiated price 44,093m list price $6,623.

* Breo elipta: negotiated price $67, list price $397.

* Xifaxan: negotiated price 41,000, list price $2,696.

* Vrayla: negotiated price $770, list price $1,376.

* Tradjenta: negotiated price $78, list price $488.

* Janument and Janunet XR: negotiated price $8, list price $526.

* Otezla: negotiated price $1,650, list price $4,722.

Contributing Reuters

HOME